Medicine and Life Sciences - Life Sciences

A research team from the University of Valencia has analysed the scientific evidence available suggesting that cancer and cardiovascular disease are not independent conditions but share important metabolic and biological mechanisms. This synthesis of current knowledge, published in Seminars in Cancer Biology , proposes an integrative perspective that could help rethink the prevention and treatment of both diseases.

The University of Valencia (UV) and the Raminatrans Foundation have signed a sponsorship agreement under which the private entity will contribute €12,000 to support Liver cirrhosis causes approximately 170,000 deaths annually in Europe, accounting for 1.8% of all deaths. The study is being conducted by the Grup d'Investigació de Deteriorament Neurològic at the UV, led by Carmina Montoliu, professor in the Department of Pathology.

The University of Barcelona is consolidating its position at the forefront of European research thanks to the strategic project "VISI-ON-BRAIN: Cutting-edge Human In Vitro and In Silico Biomedical Tools on Brain Disorders".

The Universitat de València participates in a new study, conducted by Institut d'Investigació Sanitària INCLIVA and Hospital Clínic Universitari de València, which explores the impact of the microbiota, or commensal flora, on the prognosis of the patients affected with lymphoma that receive CAR-T therapy, a treatment for cancer where the patient cells are genetically modified to recognise and attack specific cancer cells.

The gilthead seabream, a species of commercial interest that migrates seasonally, does not form independent local populations in the north-western Mediterranean but instead constitutes a single, functionally connected population on a large scale.

A research team from the University of Valencia (UV), the INCLIVA Health Research Institute and CIBERER , in collaboration with international reference centres and the biotechnology company Arthex Biotech , has developed a novel therapeutic strategy that opens a realistic pathway towards treating myotonic dystrophy type 1 (DM1), a rare and progressive neuromuscular disorder for which there is currently no effective treatment.